Cancer

February 12, 2019

Natural product-derived Combination therapy for Squamous cell carcinoma of head and neck (HNSCC): A therapeutic mix encompassing  a therapeutic mix encompassing Metformin and Navitoclax/ABT-263   inhibits BMI1 and AP-1 expression, overcomes chemotherapeutic resistance, promotes chemosensitivity, suppresses cancer stem cells in HNSCC, and inhibits lymph node metastasis, via down-regulation of its target genes, 12/February/2017, 10.13 pm

Introduction: What they say: A study from the Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, Jonsson Comprehensive Cancer Center and Broad Stem Cell Research […]
February 10, 2019

Combinatorial therapy for Metastatic human tumors:  A pharmaceutical mixture encompassing metformin and Navitoclax/ABT-263 (MAN)  decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via upregulation of its target gene, 11/February/2017, 12.34 am

Introduction: What they say: A study from the State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen […]
February 10, 2019

Combinatorial therapy for Acute Myeloid Leukemia:  A pharmaceutical mixture encompassing Metformin and Navitoclax/ABT-263 (MAN) decreases the expression of BCLAF1,  promotes differentiation of acute myeloid leukaemia cells, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and promotes regression of AML via up-regulation of its target gene, 10/February/2019, 11.27 pm

Introduction: What they say: A study from the Institute of Genetics and Biophysics, CNR, Naples, Italy; and Department of Biochemistry, Biophysics and General Pathology, Second University […]
February 9, 2019

Combinatorial therapy for metastatic prostate cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) inhibits the expression of CDC42, CDC42EP3, RAC1 and ARPC5, and GAS6, suppresses the expression of stem cell molecules CD44 and EZH2, promotes epithelial phenotype, suppresses tumorigenesis, migration, invasion, stem cell regeneration and metastasis via upregulation of its target gene, 9/February/2018, 6.53 am

Introduction: What they say: A study from the Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Science Park, Texas 78957, USA […]